Terns Pharmaceuticals Inc
$ 41.50
-0.05%
29 Dec - close price
- Market Cap 4,516,018,000 USD
- Current Price $ 41.50
- High / Low $ 41.83 / 40.90
- Stock P/E N/A
- Book Value 3.25
- EPS -1.02
- Next Earning Report 2026-03-31
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.20 %
- ROE -0.29 %
- 52 Week High 48.26
- 52 Week Low 1.86
About
Terns Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Foster City, California, focused on pioneering small-molecule therapies for nonalcoholic steatohepatitis (NASH) and other significant chronic liver diseases. With a robust pipeline of single-agent and combination therapy candidates, Terns is strategically positioned to address critical unmet medical needs within the hepatology field. The company's commitment to advancing innovative treatments not only has the potential to significantly improve patient outcomes but also represents a compelling investment opportunity for institutional investors seeking exposure to the evolving landscape of liver disease therapeutics.
Analyst Target Price
$53.56
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-10 | 2025-08-05 | 2025-05-12 | 2025-03-12 | 2024-11-12 | 2024-08-05 | 2024-05-13 | 2024-03-14 | 2023-11-14 | 2023-08-08 | 2023-05-15 | 2023-03-27 |
| Reported EPS | -0.27 | -0.26 | -0.26 | -0.24 | -0.28 | -0.31 | -0.3 | -0.29 | -0.42 | -0.25 | -0.31 | -0.29 |
| Estimated EPS | -0.3021 | -0.2918 | -0.2702 | -0.3002 | -0.32 | -0.34 | -0.34 | -0.29 | -0.31 | -0.34 | -0.27 | -0.43 |
| Surprise | 0.0321 | 0.0318 | 0.0102 | 0.0602 | 0.04 | 0.03 | 0.04 | 0 | -0.11 | 0.09 | -0.04 | 0.14 |
| Surprise Percentage | 10.6256% | 10.8979% | 3.775% | 20.0533% | 12.5% | 8.8235% | 11.7647% | 0% | -35.4839% | 26.4706% | -14.8148% | 32.5581% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-31 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.2999 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TERN
2025-12-23 13:09:47
Terns Pharmaceuticals recently announced strong Phase 1 results for TERN-701, a chronic myeloid leukemia candidate, showing high response rates and supporting its advancement to Phase 2. While this data strengthens Terns' investment narrative by highlighting TERN-701 as a key catalyst, the company's valuation, lack of revenue, widening losses, and ongoing dilution remain significant concerns for investors. The stock's recent performance reflects both optimism from the clinical data and caution regarding the company's financial health and dependency on a single lead asset.
2025-12-23 13:09:47
Terns Pharmaceuticals (TERN) shares soared over 53% after presenting positive interim data for its leukemia treatment, TERN-701, at the American Society of Hematology Annual Meeting. The trial showed significant clinical responses and an encouraging safety profile in patients with chronic myeloid leukemia (CML), suggesting a promising new option for CML patients.
2025-12-22 11:09:57
Terns Pharmaceuticals (TERN) recently announced positive Phase 1 results for its chronic myeloid leukemia candidate TERN-701, showing strong molecular response rates and supporting its advancement to Phase 2 trials. Despite this promising data, the stock experienced a 7.7% decline, raising questions about whether the positive clinical outcome was already priced into the stock. The company faces ongoing challenges with its premium valuation, cash burn, and recurrent equity raises, which continue to be central concerns for investors, especially given its reliance on a single lead asset.
2025-12-21 13:09:47
This article reports a significant increase in the price target for Terns Pharmaceuticals (TERN), with an adjustment of 75.91% to $54.63. The article is very concise and only relays this single piece of information.
2025-12-21 08:09:04
This article is a placeholder with very limited information. It indicates that Jim Cramer highlighted significant gains for Terns Pharmaceuticals shareholders. No further details about the gains or the company are provided in the content.
2025-12-19 15:14:00
Jim Cramer discussed Terns Pharmaceuticals, Inc. (NASDAQ: TERN) following a caller's substantial gains after buying the stock low and seeing it surge. The company recently announced positive Phase 1 results for its drug TERN-701, showing promising efficacy in treating chronic myeloid leukemia. Cramer advised the caller that they had already won big and didn't need to push their luck further.
